- See our top-yielding stocks list.
The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.
The Swiss biotech was last year reported to be a target of Shire.
Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?
Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.